Alliance for Pandemic Preparedness

April 9, 2021

Poor Anti-SARS-CoV-2 Humoral and T-Cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept

Category:

Topic:

Keywords (Tags):

  • A study of kidney transplant recipients receiving belatacept (N=101), a drug to prevent organ rejection, found that humoral and T-cell immune response to the Pfizer-BioNTech vaccine was low. Only 2 patients developed spike antibodies 28 days after the first dose and 2 of 35 patients tested one month after the 2nd dose developed antibodies. A specific T-cell response was observed in only 2 of 40 patients tested 28 days after the first dose and in 7 of 23 patients tested 1 month after the 2nd dose. The authors recommend that kidney transplant recipients receiving belatacept should continue to maintain distancing and masking and household members should be vaccinated to maintain protection against COVID-19.

Chavarot et al. (Apr 8, 2021). Poor Anti-SARS-CoV-2 Humoral and T-Cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept. Transplantation. https://doi.org/10.1097/TP.0000000000003784